INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the outcome of its Annual General Meeting (“AGM”) which took place on June 29, 2011, in Marseilles, France.

Transparency directive : regulatory news

29/06/2011 17:52

PRESS RELEASE

INNATE PHARMA'S ANNUAL GENERAL MEETING OF JUNE 29, 2011: ALL PROPOSED
RESOLUTIONS WERE VOTED ACCORDING TO MANAGEMENT'S RECOMMENDATIONS

Marseilles, France, June 29, 2011

Innate Pharma (Euronext Paris: FR0010331421 - IPH) announces today the outcome
of its Annual General Meeting ("AGM") which took place on June 29, 2011, in
Marseilles, France.

A number of 26,483,176 votes were expressed out of a total of 37,568,383
shares with voting rights, representing a quorum of 70.5%. All resolutions
were voted in accordance with the management's recommendations. Details of the
votes are available on Innate Pharma's website, "investors section".

During the AGM, the Board members mandates were renewed and Alta BioPharma
Partners II, LP, represented by Ms Ekaterina Smirnyagina, was appointed as a
new member of the Supervisory Board.

The AGM was followed by a meeting of the Supervisory Board on the same day,
which appointed Mr Gilles Brisson as Chairman and Ms Irina Staatz-Granzer as
Vice-Chairman of the Supervisory Board.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its most advanced drug-candidate is IPH 2101, an anti-KIR monoclonal
antibody potentiating NK cells activation currently in Phase II clinical
trials in hematologic cancers. Two of its antibody programs in chronic
inflammation are out-licensed to Novo Nordisk A/S.

Innate Pharma's key expertise is in immunopharmacology and antibody
technology. The Company has implemented in-house a large panel of molecular
and cellular assays and in vivo models for assessing the pharmacodynamics and
pharmacotoxicology of drug candidates. In addition, Innate Pharma has access
to a very large set of unique research tools in cellular immunology through
its worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 85 employees as at
March 31, 2011.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code               FR0010331421
Ticker code             IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                      Alize Public Relations
Laure-Hélène Mercier               Caroline Carmagnol
Director, Investor Relations       Phone:  +33 (0)1 42 68 86 43
Phone: +33 (0)4 30 30 30 87        Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com        caroline@alizerp.com

PH_AGM 2011 results

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the outcome of its Annual General Meeting (“AGM”) which took place on June 29, 2011, in Marseilles, France.

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories